论文部分内容阅读
目的 :探讨急性髓系白血病 (AML)的原发性耐药蛋白 p170、GSTP- 1等的表达和疗效、预后的关系。方法 :采集 AML 患者治疗前骨髓液 ,采用 ABC- AP法检测 p170、GSTP- 1和其他单抗。结果 :110 5例初治 AML中 12例 (11.4% )出现 p170或 GSTP- 1的阳性表达。 2耐药表达阳性的 12例中 CR6例 (5 0 % ) ,有效率为6 6 .7% ;12例中目前 7例死亡 ,2例复发 ,总生存曲线下降较快。无病生存曲线反映 18个月追踪仅剩 2 5 %左右。结论 :成人 AML原发性耐药的表达是治疗效果差的标志之一 ,与预后直接相关。
Objective: To investigate the relationship between the expression of primary resistance protein p170 and GSTP-1 in acute myeloid leukemia (AML) and their curative effect and prognosis. Methods: The bone marrow fluid of AML patients before treatment was collected. The p170, GSTP-1 and other monoclonal antibodies were detected by ABC-AP assay. Results: The positive expression of p170 or GSTP-1 in 110 of 5 untreated AML cases was found in 11 cases (11.4%). 2 CR6 positive (50%), the effective rate was 6 6 .7%. Of the 12 cases, 7 cases died and 2 cases relapsed, the overall survival curve decreased rapidly. The disease-free survival curve reflects only around 25% of the remaining 18 months of follow-up. Conclusion: The expression of primary drug resistance in adult AML is one of the markers of poor therapeutic effect, which is directly related to the prognosis.